Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
Open Access
- 14 December 1995
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 333 (24) , 1588-1594
- https://doi.org/10.1056/nejm199512143332402
Abstract
Despite doubts about their efficacy and concern about their safety, antithrombotic agents are often used to treat acute ischemic stroke. Recent experience in patients with other thromboembolic disorders suggests that low-molecular-weight heparin, which requires only subcutaneous administration once or twice daily, may be more effective and safer than standard (unfractionated) heparin.Keywords
This publication has 28 references indexed in Scilit:
- Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated HeparinNew England Journal of Medicine, 1995
- Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.Stroke, 1994
- Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke.Stroke, 1994
- Interobserver reliability of a clinical classification of acute cerebral infarction.Stroke, 1993
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke, 1993
- Antithrombotic Therapy for Ischemic Cerebrovascular DiseaseSeminars in Neurology, 1991
- Classification and natural history of clinically identifiable subtypes of cerebral infarctionPublished by Elsevier ,1991
- An alternative view of heparin anticoagulation in acute focal brain ischemia.Stroke, 1989
- Heparin anticoagulation.Stroke, 1989
- Heparin anticoagulation in acute brain ischemia.Stroke, 1988